Navigation Links
DrugRisk Update: Byetta Lawsuits Headed to Special Federal Court
Date:9/17/2013

New York, NY (PRWEB) September 17, 2013

The diabetes drug resource center at DrugRisk.com is announcing updated information for patients taking the medication Byetta. A federal panel recently consolidated a growing number of lawsuits alleging the drug caused cancer to a multidistrict litigation court for expedited handling*.

DrugRisk seeks to improve patient safety by providing the latest recalls, safety alerts, research and litigation news to those taking popular prescription drugs. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.

Byetta is a popular injectable medication prescribed to those with type-II diabetes to lower blood sugar levels. However, the resource center has added information showing experts disagree about its safety.

In 2011, a study from UCLA suggested subjects given Byetta may have higher occurrences of pancreatic cancer and thyroid cancer**. This year, the Journal for the American Medical Association also advised that drugs like Byetta can double the risk of pancreatitis, a major risk factor for pancreatic cancer***.

The Institute for Safe Medication Practices has attributed a majority of serious diabetes drug side effect reports to the FDA to Byetta****. However, the FDA has not issued a recall or required new warning labels.

Now, DrugRisk has learned that, due to the growing number of patients who have filed a Byetta lawsuit alleging cancer, the Judicial Panel on Multidistrict Litigation has consolidated cases to a special multidistrict litigation federal court. (In Re: Incretin-Based Therapies Products Liability Litigation, MDL 2452, Southern District of California)*.

Anyone affected by cancer after taking Byetta is encouraged to visit the DrugRisk center or speak with a lawyer about their legal options. However, DrugRisk only recommends lawyers who have already handled these complex Byetta lawsuits.

For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML 8/26/13; jpml.uscourts.gov/sites/jpml/files/MDL-2452-Initial_Transfer-07-13.pdf
**Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****ISMP QuarterWatch April, 2013.ismp.org/QuarterWatch/pdfs/2012Q3.pdf

Read the full story at http://www.prweb.com/releases/byetta-pancreatic-thyroid/cancer-symptoms/prweb11130048.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Update: Januvia Lawsuits Alleging Cancer Headed to Federal Court
2. DrugRisk Update: Latest Court Order Moves Mirena Lawsuits Forward
3. DrugRisk News: Court Consolidates Januvia Lawsuits Alleging Cancer
4. DrugRisk Update: Court Issues Latest Decision in Pradaxa Bleeding Litigation
5. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
6. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
7. DrugRisk Announces Latest Ruling By Judicial Panel on NuvaRing Lawsuits
8. DrugRisk Announces Drop in Yaz Lawsuits As Bayer Commits $1.5 Billion to Settlements
9. DrugRisks Announces Yaz Center With Latest Updates on Blood Clot Warnings and Settlements
10. DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding
11. DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: